Day One Biopharmaceuticals, Inc.
DAWN
$6.56
$0.26454.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 161.92M | 131.16M | 101.95M | 8.19M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 161.92M | 131.16M | 101.95M | 8.19M | -- |
| Cost of Revenue | 8.16M | 5.28M | 2.30M | 707.00K | -- |
| Gross Profit | 153.76M | 125.88M | 99.66M | 7.49M | -- |
| SG&A Expenses | 118.22M | 115.45M | 107.88M | 97.19M | 84.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 353.49M | 343.43M | 308.41M | 295.72M | 221.98M |
| Operating Income | -191.57M | -212.27M | -206.46M | -287.53M | -221.98M |
| Income Before Tax | -61.94M | -88.35M | -83.62M | -165.93M | -208.94M |
| Income Tax Expenses | 7.14M | 7.14M | 670.00K | 1.55M | -- |
| Earnings from Continuing Operations | -69.08 | -95.50 | -84.29 | -167.48 | -208.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.08M | -95.50M | -84.29M | -167.48M | -208.94M |
| EBIT | -191.57M | -212.27M | -206.46M | -287.53M | -221.98M |
| EBITDA | -189.21M | -210.71M | -205.50M | -287.17M | -221.92M |
| EPS Basic | -0.66 | -1.03 | -1.02 | -1.94 | -2.50 |
| Normalized Basic EPS | -0.37 | -0.56 | -0.60 | -1.17 | -1.53 |
| EPS Diluted | -0.66 | -1.03 | -1.03 | -1.95 | -2.51 |
| Normalized Diluted EPS | -0.37 | -0.56 | -0.60 | -1.17 | -1.53 |
| Average Basic Shares Outstanding | 388.90M | 372.87M | 356.47M | 345.80M | 333.64M |
| Average Diluted Shares Outstanding | 389.21M | 373.18M | 356.78M | 345.80M | 333.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |